Kengo Onochi

Kengo Onochi

Auto-generated profile, based on publicly available information

Kengo Onochi

Division of Gastroenterology, Omagari Kosei Medical Center

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in The Tohoku Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TYTatsuki Yoshida
Tatsuki Yoshida
YSYosuke Shimodaira
Yosuke Shimodaira
SFSho Fukuda
Sho Fukuda
NWNoboru Watanabe
Noboru Watanabe
SKShigeto Koizumi
Shigeto Koizumi
KIKatsunori Iijima
Katsunori Iijima
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

25 December 2007 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
OTOsamu Takasawa
Osamu Takasawa
NFNaotaka Fujita
Naotaka Fujita
YNYutaka Noda
Yutaka Noda
GKGo Kobayashi
Go Kobayashi
KIKei Ito
Kei Ito
TSTakashi Sawai
Takashi Sawai

30 April 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
YSYosuke Shimodaira
Yosuke Shimodaira
KOKengo Onochi
Kengo Onochi
KWKenta Watanabe
Kenta Watanabe
STSo Takahashi
So Takahashi
SFSho Fukuda
Sho Fukuda
KIKatsunori Iijima
Katsunori Iijima
Background/Aims: 5-Aminosalicylic acid (5-ASA) is a basic drug for inducing and maintaining remission for ulcerative colitis. One of its formulations has a coating with a pH-dependent degradation that ensures the release 5-ASA at the terminal ileum. No evidence has been shown concerning the effects of proton pump inhibitors (PPIs) or H2 receptor antagonists (H2RAs) on the clinical course of ulcerative colitis patients in remission. The present study assessed the effect of PPIs or H2RAs on the relapse of ulcerative colitis patients in clinical remission maintained by pH-dependent released 5-ASA.Methods: Ulcerative colitis patients who had been prescribed time- or pH-dependent-released 5-ASA between January 2015 and December 2018 were enrolled in this multicenter retrospective study. The period of remission until relapse occurred was analyzed among the patients taking time-dependent-released 5-ASA or pH-dependent-released 5-ASA with/without PPIs or H2RAs.Results: One hundred and nineteen patients were analyzed in this study. In the primary endpoint, the relapse rate was higher in patients taking pH-dependent-released 5-ASA and PPIs or H2RAs than in those taking the pH-dependent-released 5-ASA without PPIs or H2RAs, while the relapse rate was similar in patients taking the time-dependent-released 5-ASA with or without PPIs or H2RAs concomitantly. Patients with a short duration of disease and middle-aged patients more frequently showed relapse with PPIs or H2RAs than the other patients.Conclusions: The coadministration of PPIs or H2RAs affects the clinical course of ulcerative colitis in remission maintained by pH-dependent-released 5-ASA.